52 h. ago Trump says ‘getting along well’ with China, downplays ‘hostile’ acts

Trump says ‘getting along well’ with China, downplays ‘hostile’ acts  South China Morning Post

Politics

5 d. ago FDA Targets Gene Editing Clinical Trials in China and other “Hostile Countries”

FDA Targets Gene Editing Clinical Trials in China and other “Hostile Countries”  Crowell & Moring LLP

Events

6 d. ago China’s drug innovators bank on AI to hasten discovery to commercial success

Upstart Chinese drug innovators are joining their foreign competitors in deploying more artificial intelligence (AI) tools to reduce the costs of discoveries in an effort to shorten the route to clinical trials and commercialisation. Genscript Biotech, based in Nanjing in eastern Jiangsu province, is developing in-house AI tools - using its enzyme prediction database and an algorithm for altering the DNA sequence of a gene - to identify and optimise promising candidates based on protein...

Economics

1 week ago FDA Freezes Trials Shipping Cells to China, ‘Other Hostile Countries’

FDA Freezes Trials Shipping Cells to China, ‘Other Hostile Countries’  BioSpace

Politics

2 w. ago China proposes shorter clinical trial reviews in efforts to accelerate drug development

China proposes shorter clinical trial reviews in efforts to accelerate drug development  Fierce Biotech

Events

2 w. ago What next for He Jiankui, the human gene editor locked in limbo?

He Jiankui looked a little tired and worn as he contemplated his future. With no home and no institution to host his research, the 41-year-old biophysicist and self-proclaimed “pioneer of gene editing” was weighing up what to do next while staying at an upmarket hotel in Beijing late last month. He, who caused a global uproar in 2018 with his announcement of the world’s first gene-edited babies, planned to move to the United States to continue his research into gene-editing embryos to combat...

Politics

2 w. ago Chinese brain implant reaches landmark clinical trial with operation on amputee

China has become the second country in the world to advance invasive brain-computer interface technology to a human trial, state broadcaster CCTV reported on Saturday. The trial is on a 37-year-old man who had to have all of his limbs amputated after a high-voltage electrical accident more than a decade ago. In March, researchers implanted a device roughly the size of a coin and a series of electrodes into the man’s brain. A few weeks later, he was able to control a cursor on an electronic...

Politics

2 w. ago China and Japan must beat mutual hostility while also handling tariffs: envoy

China and Japan must work hard to improve public opinion towards each other, Japan’s top envoy in Beijing said, as the Asian neighbours move to stabilise ties amid shared concerns about tariffs imposed by US President Donald Trump. “The most difficult aspect of current Japan-China relations is the sentiment between the two peoples and, very unfortunately, there are still some negative perceptions that linger in Japan regarding China, and vice versa in the Chinese society regarding Japan,” said...

Politics

3 w. ago Trump is increasingly hostile to China. He’s playing with fire

Trump is increasingly hostile to China. He’s playing with fire  CNN

Politics

3 w. ago Biotech firm touts new AI drug discovery amid third Hong Kong IPO attempt

Biotechnology firm Insilico Medicine said its new drug for lung disease, designed with the help of artificial intelligence (AI), showed positive results in the latest clinical trials, as the company pushes for a public listing in Hong Kong. Insilico found that its new small-molecule drug candidate, rentosertib, designed with its AI platform Chemistry42, was “generally safe and potentially effective” for treating idiopathic pulmonary fibrosis (IPF), according to its phase 2A clinical trial...

Economics

last month Novo Nordisk faces fierce competition in China’s diabetes drug market

Competition in the mainland Chinese market for diabetes and weight loss drugs is set to intensify as more than 60 late-stage drug candidates are undergoing clinical trials, according to a recent report. Up to 20 biosimilar or generic copies will vie for market share and add pricing pressure after Denmark-based Novo Nordisk’s semaglutide product loses patent protection in China next year, according to Boston-based global consultancy L.E.K. Consulting. Novo Nordisk’s patent will expire in 2031 in...

Events